Connected drug delivery devices to complement drug treatments: potential to facilitate disease management in home setting.

In this analysis (n=720), a significantly higher proportion of patients treated with high-dose interferon β-1a (≥120 μg/week) were relapse-free at month 6 compared with patients with lower doses (92.5% vs 86.7%, respectively), and a nonsignificant trend was observed at month 12/ED (82.1% vs 76.6%).

also in 5,406 other papers